Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
External Resources
Posted by 
Last updated and reviewed on: January 05, 2025FDA-Approved Fixed-Duration CLL Therapies
- Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial - The Lancet Oncology
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions | New England Journal of Medicine
- Fixed-Duration Venetoclax Plus Obinutuzumab as First-Line Treatment in Older Patients With CLL Who Have Comorbidities
- 1908 Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
- Venclexta for Previously Treated CLL/SLL
- Venclexta Prescribing Information
- Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
- Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
- Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
- Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen - PMC
- Chronic Lymphocytic Leukemia Treatment Algorithm 2022
- What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
- CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers
- 330 Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004
FDA-Approved Continuous-Duration CLL Therapies
- What are BTK Inhibitors for CLL?
- Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study
- Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
- Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | Journal of Clinical Oncology
- Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
- Next-Generation Targeted Therapy Zanubrutinib Found Superior to Ibrutinib for CLL and SLL - Hematology.org
- Brukinsa Patient Brochure
- Paper: Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
- What are BTK Inhibitors for CLL?
Side Effect Management of CLL Therapies
- Managing toxicities of Bruton tyrosine kinase inhibitors
- Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
- The Role of Mitochondrial Stress and the Late Sodium Current in Ibrutinib-Mediated Atrial Fibrillation
- Breyanzi Prescribing Information
- Cytokine release syndrome
- Grading of cytokine release syndrome associated with the CAR T cell therapy
- Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
- CAR T-Cell Grading and Management: ICANS
- In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
- Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
- Managing toxicities of Bruton tyrosine kinase inhibitors
- Ibrutinib-associated Arthralgias/Myalgias in Patients with Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
- Venclexta
- Does Reducing My Ibrutinib Dose Impact My CLL Outcome?
- How Does Inflammation Influence CLL?
- Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies
- Immunoglobulin Therapy or Antibiotics: Which is More Effective in Preventing CLL Patient Infections?
- Managing Fatigue, Anemia, and GI CLL Side Effects with Nutrition
- Cytopenia
Considerations for Treatment Selection
- Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management
- Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population
- Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study
- Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
- Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study
- Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management
- Do CLL Patients Prefer Fixed-Duration or Continuous-Duration Therapy?
CLL Financial Resources
- Medicare Prescription drugs (outpatient)
- What Medicare Part D drug plans cover
- Medicare Chemotherapy
- Drug Policy: Gazyva (obinutuzumab)
- CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)
- CMS Oncology Care Model
- Drugs excluded from Part D coverage
- Parts of Medicare
- Inflation Reduction Act Research Series— Medicare Part D Enrollee Out-Of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
- Financial Considerations for CAR T-cell Therapy Patients
- Final CY 2026 Part D Redesign Program Instructions
The Future of CLL Treatment
- Precision diagnostics in chronic lymphocytic leukemia: Past, present and future
- Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
- Broadening the horizon: potential applications of CAR-T cells beyond current indications
- Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
- BTK inhibitors in CLL: second-generation drugs and beyond
- Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
- Revolutionizing chronic lymphocytic leukemia diagnosis: A deep dive into the diverse applications of machine learning
- Racial and Socioeconomic Disparities Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in the US Community Oncology Setting